TrDizin

Permanent URI for this collectionhttps://hdl.handle.net/11452/21452

Browse

Browsing by Author "0000-0001-5761-4757"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The danger awaiting premature babies: Portal vein thrombosis
    (Türk Milli Pediatri Derneği, 2020-03-30) Çakır, Salih Çağrı; Özkan, Hilal; Dorum, Bayram Ali; Köksal, Nilgün; Kudretoğlu, Pınar; Baytan, Birol; Sezgin, Melike; Güneş, Adalet Meral; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/Yenidoğan Bilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/Çocuk Hematolojisi Bilim Dalı.; 0000-0001-5761-4757; AAG-8393-2021; 57205555920; 16679325400; 37661266800; 7003323615; 57219225102; 6506622162; 55316683800; 24072843300
    Aim: Umbilical venous catheters are frequently used in the neonatal period. The incidence of umbilical venous catheter-related thrombosis is between 1.3% and 43% in ultrasound scans. This study aimed to determine the incidence and risk of portal vein thrombosis in patients who were hospitalized in the neonatal intensive care unit and underwent umbilical venous catheter insertion. Material and Methods: Premature infants (<= 32 gestational weeks) who were hospitalized in a Level III neonatal intensive care unit and underwent umbilical vein catheter placement between 2016 and 2018, were included in the study. The demographic data, clinical risk factors for thrombosis, number of catheter days, catheter locations, times of detection of thrombosis using Doppler ultrasonography, treatment methods and durations, thrombosis follow-up and examinations were obtained retrospectively from the electronic patient files. Results: Ninety-six patients whose complete data could be reached were enrolled in the study. The mean gestational age of the patients was found as 29 +/- 2 weeks and the mean birth weight was 1353 +/- 369 g. Portal vein thrombosis was detected in 13.5% (n=13) of the patients. Five of the cases of portal vein thrombose were complete occlusion and eight were partial occlusion. All patients with complete occlusion and six patients with partial occlusion were treated with low-molecular-weight heparin for a mean duration of 31 +/- 13.8 days. Thrombosis disappeared in 7-120 days in all patients. A thrombophilia mutation was detected in six patients with thrombosis, four of whom had the PAI-1 4G / 5G mutation. Conclusion: Portal vein thrombosis which has a significant place among the causes of portal hypertension in childhood, is mostly asymptomatic in the neonatal period and cannot be recognized clinically. It is important to screen and follow up patients with umbilical vein catheters using Doppler ultrasonography in terms of PVT after catheter removal to prevent long-term complications.
  • Thumbnail Image
    Item
    Does antenatal magnesium sulphate improve hearing function in premature newborns?
    (Galenos Yayıncılık, 2019-12-02) Kasapoğlu, Işıl; Çetinkaya, Bilge Demir; Altay, Mehmet Aral; Orhan, Adnan; Özkan, Hilal; Çakır, Salih Çağrı; Toker, Rabia tütüncü; Kasapoğlu, Fikret; Özerkan, Kemal; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun Boğaz Anabilim Dalı.; 0000-0002-3129-334X; 0000-0002-7558-8166; 0000-0001-6845-9991; 0000-0001-5761-4757; 0000-0002-9685-956X; ABI-4540-2020; V-5292-2019; AAH-9834-2021; AAH-9791-2021; A-8779-2013; 55800494800; 36923039100; 53863297800; 56671094200; 16679325400; 57205555920; 55958250400; 56254721200; 6603345841
    Objective: To evaluate whether antenatal magnesium sulphate (MgSO4) exposure has a neuroprotective effect against hearing impairment in premature newborns. Material and Methods: Retrospective cohort study was performed with prematurely (<37 weeks) delivered newborns at a tertiary university hospital. Newborns of 92 women who received MgSO4 infusions (study group) for various indications were compared to newborns of 147 women who did not receive MgSO4 infusions (control group). All eligible premature newborn underwent hearing screening by auditory brainstem response (ABR) testing before being discharged from the hospital. Results: The fail rate for ABR hearing screening was 3.3% (n= 3) in the study group and 10.9% (n=16) in the control group (p=0.034). The rate of concurrent use of betamethasone was higher in the study group (72.8%; n=67) compared to control group (29.2%; n=43) (p<0.001). Other neonatal parameters, such as the number of neonates who were small for gestational age and the rate of microcephaly were similar between the groups (p=0.54, p=0.48, respectively). After adjusting for co-variates including the use of betamethasone and gestational age at delivery, no statistically significant association between antenatal administration of MgSO4 and ABR fail rates were found (p=0.07). Conclusion: These results do not suggest a significant benefit in terms of hearing impairment in premature newborns when antenatal MgSO4 infusion was given.